As of September 30, 2026, Ascelia Pharma AB carries a market capitalization of 105.76M, placing it among publicly traded companies globally. Its enterprise value stands at 78.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 105.76M |
| Enterprise Value | 78.27M |
Ascelia Pharma AB's next confirmed earnings release is scheduled for February 11, 2027.
| Earnings Date | 2/11/2027 |
As of September 30, 2026, Ascelia Pharma AB has 133.54M shares outstanding.
| Shares Outstanding | 133.54M |
These figures are as of September 30, 2026.
| PB Ratio | 1.33 |
| P/TBV Ratio | 4.68 |
| P/FCF Ratio | -1.67 |
| P/OCF Ratio | -1.67 |
As of September 30, 2026, Ascelia Pharma AB maintains a current ratio of 3.12, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.40, indicating conservative leverage, while an interest coverage ratio of -59.42 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.12 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -59.42 |
Over the twelve months ended September 30, 2026, Ascelia Pharma AB posted a negative return on equity (ROE) of -56.41, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -48.30, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -56.41 |
| Return on Assets (ROA) | -48.30 |
| Employee Count | 10.00 |
Over the twelve months ended September 30, 2026, Ascelia Pharma AB recorded an income tax benefit of -709,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -55.46M and -54.75M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -709,000.00 |
As of the close on November 17, 2026, Ascelia Pharma AB's stock has declined approximately 79.97% over the past 52 weeks. The 50-day moving average sits at 0.62, while the 200-day moving average is 1.82.
| 52-Week Price Change | -79.97% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 1.82 |
Over the twelve months ended September 30, 2026, Ascelia Pharma AB generated - - in revenue and converted that into -54.75M in net income, yielding earnings per share of -0.42. EBITDA reached -55.44M, while operating income came in at -55.44M.
| Operating Income | -55.44M |
| Pretax Income | -55.46M |
| Net Income | -54.75M |
| EBITDA | -55.44M |
| EBIT | -55.44M |
| Earnings Per Share (EPS) | -0.42 |
As of September 30, 2026, Ascelia Pharma AB holds 27.80M in cash and equivalents against 315,000.00 in total debt, resulting in a net debt position of -27.77M. Total book value stands at 79.69M, with working capital of 22.35M providing operational flexibility.
| Cash & Cash Equivalents | 27.80M |
| Total Debt | 315,000.00 |
| Net Debt | -27.77M |
| Equity (Book Value) | 79.69M |
| Book Value Per Share | 0.60 |
| Working Capital | 22.35M |
Ascelia Pharma AB produced -61.66M in operating cash flow over the twelve months ended September 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -61.66M - equivalent to -0.48 per share.
| Operating Cash Flow | -61.66M |
| Free Cash Flow | -61.66M |
| FCF Per Share | -0.48 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -59.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.35, meaning Ascelia Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -16.35 |
| FCF Yield | -59.98 |
Ascelia Pharma AB's most recent stock split took place on August 15, 2024 with a 200:289 split ratio.
| Last Split Date | 8/15/2024 |
| Split Ratio | 200:289 |
As of September 30, 2026, Ascelia Pharma AB has an Altman Z-Score of -34.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -34.16 |
Already premium?